Upstream Bio (NASDAQ:UPB) Sees Strong Trading Volume - Still a Buy?

Key Points

• Upstream Bio's stock experienced a trading volume of 352,890 shares, nearly matching the previous day's volume, with the stock price rising from $17.13 to $17.97.
• Analysts have upgraded Upstream Bio from a "sell" to a "hold" rating, with a consensus rating of "Buy" and a target price of $56.50.
• The company recently reported a quarterly loss of ($0.74) per share, which was lower than the expected loss of ($0.61), and had a revenue of $0.94 million against a consensus estimate of $0.32 million.

Upstream Bio, Inc. (NASDAQ:UPB - Get Free Report) saw strong trading volume on Tuesday . 352,890 shares traded hands during trading, a decline of 0% from the previous session's volume of 354,177 shares.The stock last traded at $17.97 and had previously closed at $17.13.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded Upstream Bio from a "sell" rating to a "hold" rating in a report on Friday, June 6th. Four research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Upstream Bio presently has a consensus rating of "Buy" and a consensus price target of $56.50.

Upstream Bio Stock Performance

The company's fifty day moving average is $14.80 and its 200-day moving average is $10.90.

Upstream Bio (NASDAQ:UPB - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.61) by ($0.13). The firm had revenue of $0.94 million during the quarter, compared to analysts' expectations of $0.32 million. Upstream Bio had a negative net margin of 3,836.58% and a negative return on equity of 35.90%. As a group, equities analysts predict that Upstream Bio, Inc. will post -4.3 EPS for the current year.

Institutional Investors Weigh In On Upstream Bio

Large investors have recently added to or reduced their stakes in the company. BNP Paribas Financial Markets bought a new stake in shares of Upstream Bio in the 4th quarter worth approximately $25,000. New York State Common Retirement Fund acquired a new stake in Upstream Bio in the 1st quarter valued at $29,000. Legal & General Group Plc raised its stake in Upstream Bio by 83.0% in the second quarter. Legal & General Group Plc now owns 3,174 shares of the company's stock valued at $35,000 after buying an additional 1,440 shares during the period. CWM LLC grew its position in Upstream Bio by 107.5% during the second quarter. CWM LLC now owns 3,312 shares of the company's stock worth $36,000 after buying an additional 1,716 shares in the last quarter. Finally, Ameritas Investment Partners Inc. raised its holdings in Upstream Bio by 95.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 3,558 shares of the company's stock valued at $39,000 after buying an additional 1,736 shares during the last quarter.

About Upstream Bio

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.